Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (886)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05339581 | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation(iPLENTY-pvtt) | unknown | N/A | 78 | RenJi HospitalOTHER | 1 | Apr 27, 2022 |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 68 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04675866 | Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer | unknown | N/A | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05319392 | Transcriptomic Signatures in Gastric Adenocarcinoma(GAC) | unknown | — | 48 | Sanjay Gandhi Postgraduate Institute of Medical SciencesOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05171439 | Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | unknown | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05315830 | A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric | unknown | Phase 1 | 10 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05317351 | A Prospective Randomized Study Comparing the Adenoma Detection Yield of SC, AI and Combined AI and G-EYE® | unknown | N/A | 2,160 | Smart Medical Systems Ltd.INDUSTRY | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05024539 | Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma | unknown | — | 300 | Shujun YangOTHER_GOV | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05311319 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04943679 | Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC | unknown | — | 15 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05200221 | A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05205629 | A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02817126 | Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer(REAL) | unknown | N/A | 1,240 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05286099 | The Surveillance of Hepatocellular Carcinoma | unknown | — | 100 | Chinese PLA General HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05287165 | Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms | unknown | Early Phase 1 | 19 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05287880 | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC | unknown | — | 60 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 18, 2022 | clinicaltrials |
| NCT05253313 | Magnetic Resonance Imaging for Better Selection of Pancreatic Cancer Patients for Surgery: A Randomized Clinical Trial(MAGIPAC) | unknown | N/A | 200 | University of AarhusOTHER | 0 | Mar 16, 2022 | clinicaltrials |
| NCT05281926 | A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients | unknown | Phase 1 | 10 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05282433 | Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 45 | Zhongnan HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04390958 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT05277675 | Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)(RANT) | unknown | N/A | 160 | Southwest Hospital, ChinaOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05278195 | Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers(CHANCEsub) | unknown | — | 300 | Zhongda HospitalOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04825470 | Liver Transplantation for Unresectable GIST Liver Metastases(TRANSGIST) | unknown | N/A | 50 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05275985 | 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma | unknown | N/A | 80 | Peking Union Medical College HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05270642 | Plan for Microwave Thermal Field | unknown | N/A | 5 | Chinese PLA General HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03917966 | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC | unknown | Phase 2 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05265962 | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 85 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Mar 4, 2022 | clinicaltrials |
| NCT03322280 | TACE Combined With Iodine-125 Seeds Implantation for HCC | unknown | N/A | 270 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04812808 | Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma(BAZE) | unknown | N/A | 10 | Hôpital FribourgeoisOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05242237 | Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform | unknown | — | 300 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05242757 | Clinical Study of MAK Immune Cells in the Treatment of PHC | unknown | N/A | 12 | Zhongnan HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05240404 | Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | unknown | Phase 2 | 116 | Xiangya Hospital of Central South UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02009176 | Laparoscope Anatomical and Aon-anatomical Hepatectomy | unknown | N/A | 110 | Shuguo Zheng, MDOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05118451 | A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC | unknown | N/A | 420 | Zhujiang HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05233358 | HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure | unknown | N/A | 176 | The Central Hospital of Lishui CityOTHER | 0 | Feb 10, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Apr 27, 2022source: clinicaltrials